TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

TREACE MEDICAL CONCEPTS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$3.88+0.01 (+0.26%)

Close on Oct 19, 2026

Market cap: $252.39M
P/E (TTM): –
Dividend yield: –

TREACE MEDICAL CONCEPTS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31
Revenue	205	207	213	219	214	211	209	203	199	196	187	175	167	155	142	126	114	105	94	85	78	65	57
Cost of Revenue	42	42	43	44	42	42	41	39	38	37	35	33	31	28	26	22	20	19	17	17	15	13	12
Gross Profit	163	165	170	175	171	169	168	164	160	159	152	142	136	127	116	104	94	86	78	68	62	51	45
Research & Development	18	19	20	21	21	21	21	20	19	17	15	15	14	14	14	13	12	11	10	8.75	7.72	6.28	5.85
Selling, General & Admin	199	202	204	202	198	201	203	206	206	198	188	175	163	153	138	127	113	98	84	67	57	44	38
Selling & Marketing	136	139	141	140	139	143	148	151	151	148	141	131	123	116	105	98	88	76	65	54	46	36	32
General & Administrative	62	63	63	62	59	57	56	56	55	51	47	44	40	37	33	30	25	22	18	13	11	8.01	6.54
Operating Expenses	217	221	224	223	219	221	224	226	225	215	203	190	178	167	151	141	125	109	94	76	64	51	44
Operating Income	-54	-56	-54	-48	-48	-52	-56	-62	-65	-57	-51	-48	-42	-41	-35	-37	-31	-23	-17	-7.28	-1.88	0.65	0.86
Interest Expense	5.82	5.58	5.32	5.28	5.26	5.25	5.26	5.25	5.23	5.20	5.17	5.17	5.07	4.73	4.40	4.12	3.89	3.98	4.06	4.10	3.95	3.37	2.78
Other Non-Operating Income	-5.79	-5.30	-4.85	-1.67	-1.29	-0.69	-0.06	0.74	1.27	1.87	1.90	0.49	-0.63	-6.71	-7.97	-8.08	-8.22	-3.95	-4.04	-4.09	-5.72	-5.15	-4.52
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0.30	–	–	0.30	–	–	–	–	–	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	0
Net Income incl. Noncontrolling Interests	-60	-61	-59	-50	-49	-53	-56	-62	-64	-55	-50	-48	-42	-47	-43	-45	-39	-27	-21	-11	-7.60	-4.49	-3.67
Net Income	-60	-61	-59	-50	-49	-53	-56	-62	-64	-55	-50	-48	-42	-47	-43	-45	-39	-27	-21	-11	-7.60	-4.49	-3.67
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-43	-45	-39	-27	-21	-12	-8.12	-5.13	-4.31
EPS (Basic)(per share)	-0.93	-0.97	-0.93	-0.80	-0.79	-0.85	-0.90	-0.99	-1.02	-0.88	-0.81	-0.79	-0.73	-0.84	-0.77	-0.81	-0.71	-0.50	-0.43	-0.23	-0.19	-0.15	-0.12
EPS (Diluted)(per share)	-0.93	-0.97	-0.93	-0.80	-0.79	-0.85	-0.90	-0.99	-1.02	-0.88	-0.81	-0.79	-0.73	-0.84	-0.77	-0.81	-0.71	-0.50	-0.43	-0.23	-0.19	-0.15	-0.12
Shares Outstanding (Basic, Weighted)(shares)	64	64	63	63	63	62	62	62	62	62	61	59	58	56	55	55	54	53	48	44	40	37	37
Shares Outstanding (Diluted, Weighted)(shares)	64	64	63	63	63	62	62	62	62	62	61	59	58	56	55	55	54	53	48	44	40	37	37
EBITDA	-45	-47	-44	-38	-38	-43	-47	-54	-58	-50	-46	-44	-38	-38	-33	-36	-30	-22	-16	-6.65	-1.16	1.68	2.07

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 79.5%
Operating margin: -26.2%
Net margin: -29.0%
Return on equity, FY2025: -58.9%

Financial strength

Current ratio: 2.90
Debt to equity: 0.87
Debt to assets: 32.7%
Cash to current liabilities: 30.4%

Valuation

P/E ratio: –
Price to sales: 1.23
Price to book: 3.73
Dividend yield: –